Biodexa Enters Into Exclusive License To ERapa, A Phase 3 Ready Asset For The Treatment Of Familial Adenomatous Polyposis; Worldwide Rights Come With $17M In Non-Dilutive Grant Funding For Pivotal Phase 3 Trial In FAP
Biodexa Enters Into Exclusive License To ERapa, A Phase 3 Ready Asset For The Treatment Of Familial Adenomatous Polyposis; Worldwide Rights Come With $17M In Non-Dilutive Grant Funding For Pivotal Phase 3 Trial In FAP
Biodexa獲得eRapa的獨家許可，eRapa是治療家族性腺瘤性息肉病的第三階段現成資產；全球版權爲FAP的關鍵三期試驗提供1700萬美元的非稀釋性撥款
Biodexa Enters Into Exclusive License to eRapa, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)
Biodexa獲得eRapa的獨家許可，eRapa是第三階段的現成資產家族性腺瘤性息肉病（FAP）的治療
Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP
全球版權爲FAP的Pivotal 3期試驗提供了1700萬美元的非稀釋性撥款
An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum
據估計，在美國和歐洲有100,000人患有FAP，這是癌前息肉，通常會導致手術切除結腸和/或直腸
In FAP, eRapa holds the potential of delaying or preventing surgical intervention
在FAP中，eRapa有可能延遲或阻止手術干預
Multiple opportunities seen in other indications, including bladder and prostate cancers
其他適應症中有多種機會，包括膀胱癌和前列腺癌
FAP is a substantially genetic orphan disease for which there are no approved therapeutic options; the current standard...
FAP 基本上是一種遺傳性孤兒病，尚...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。